Current Issues of Chronic Hepatitis B

Size: px
Start display at page:

Download "Current Issues of Chronic Hepatitis B"

Transcription

1

2 June 22 (Fri), 2018 Postgraduate Course (I) Current Issues of Chronic Hepatitis B Room :20-15:00 Wan-Long Chuang (Kaohsiung)/ Han-Chieh Lin () 13:20-13:45 PG-1 Experience from HCV Cure Chen-Hua Liu 13:45-14:10 PG-2 Current Strategy for HBV Treatment: Benefit and Chien-Hung Chen Challenge Kaohsiung 14:10-14:35 PG-3 Hepatitis B virus infection and liver carcinogenesis Shiou-Hwei Yeh 14:35-15:00 PG-4 Clinical and Virological Significance of NTCP Receptor in HBV Koichi Watashi Tokyo Postgraduate Course (II) Possible Future Hopes for Treatment of Chronic Hepatitis B Room :20-17:00 Chia-Ho Shih ()/ Chia-Yen Dai (Kaohsiung) 15:20-15:45 PG-1 Overview of HBV Molecular Virology - Unsolved Issues and New Drug (Targets) Man-Fung Yuen Hong Kong 15:45-16:10 PG-2 Overview of HBV Immunology Mi-Hua Tao 16:10-16:35 PG-3 Prospect for the HBV Therapy from the Immunological Approach Antonio Bertoletti Singapore 16:35-17:00 PG-4 Issues after Hepatitis B Cure --- HBV Reactivation Yasuhito Tanaka Nagoya

3 June 23 (Sat), 2018 Plenary Session (I): Epidemiology Impacts of Secondary and Tertiary Prevention in Chronic Hepatitis B Elimination 08:00-09:40 08:10-08:25 PL1-1 08:25-08:50 PL1-2 08:50-09:15 PL1-3 08:15-09:40 PL1-4 Junko Tanaka (Hiroshima)/ Chia-Ming Chu () Natural History of Acute and Chronic HBV Infection Epidemiology and clinical significance of occult HBV infection Pathway from the Epidemiological Point of view; Moving towards the Elimination of HBV & HCV in Japan Global Epidemiology and Prevention of Chronic Hepatitis B Infection (TBA) Chia-Ming Chu Giovanni Raimondo Messina Junko Tanaka John W. Ward Hiroshima Atlanta Plenary Session (II): Virology Molecular Virology in New Antiviral Therapies Room 201DEF 08:00-09:40 Masashi Mizokami (Tokyo)/ Chau-Ting Yeh (Taoyuan) 08:10-08:25 PL2-1 Cell Entry Inhibition as An Antiviral Strategy Koichi Watashi Tokyo 08:25-08:50 PL2-2 Complete and Incomplete HBV particles Jianming Hu Hershey, PA 08:50-09:15 PL2-3 08:15-09:40 PL2-4 Recent Development of Capsid Modulators/ Inhibitors as New Antiviral Agents cccdna elimination new methods and difficulties Man-Fung Yuen Wenhui Lee Hong Kong Beijing

4 Plenary Session (III): Immunlogy Immunological Aspect of Chronic Hepatitis B 10:00-11:40 10:00-10:25 PL3-1 10:25-10:50 PL3-2 10:50-11:15 PL3-3 11:15-11:40 PL3-4 Antonio Bertoletti (Singapore)/ Chun-Yen Lin () The Liver Microenvironment and HBV Immunity Manipulation of the innate-adaptive immune cell axis in chronic HBV infection Cure CHB via Targeting Adaptive Immune Response: Animal Experience Cure CHB via Targeting Adaptive Immune Response Percy A. Knolle Laura Pallett Mi-Hua Tao Antonio Bertoletti Munich London Singapore Plenary Session (IV): HCV HCV: Cure and After Cure Room 201DEF 10:00-11:40 10:00-10:25 PL4-1 Geoffrey Dusheiko (London)/ Jia-Horng Kao () Epidemiology and Risk Assessment of Hepatitis C virus Infection in Taiwan Mei-Hsuan Lee 10:25-10:50 PL4-2 Current Treatment of HCV Chen-Hua Liu 10:50-11:15 PL4-3 Unmet needs of chronic hepatitis C after SVR Ming-Lung Yu Kaohsiung 11:15-11:40 PL4-4 How to Achieve Global HCV Elimination by 2030? Geoffrey Dusheiko London Plenary Session (V): HBV Challenges and Opportunities in the Diagnosis and Outcomes Prediction of Chronic HBV Infection 13:00-14:40 13:00-13:25 PL5-1 13:25-13:50 PL5-2 13:50-14:15 PL5-3 14:15-14:40 PL5-4 Yasuhito Tanaka (Nagoya)/ Chun-Jen Liu () Advances in the Serologic and Virologic Diagnosis of HBV Infection Application of Circulating DNA to HBV Induced Liver Pathogenesis Application of HCC Risk Scores in Management of CHB Patients Non-invasive Prediction of HBV Treatment Outcomes Including HCC Yasuhito Tanaka Shiou-Hwei Yeh Hwai-I Yang Grace Wong Nagoya Hong Kong

5 Plenary Session (VI): HDV Toward Global HDV Control in General and High Risk Populations Room 201DEF 13:00-14:40 13:00-13:25 PL6-1 13:25-13:50 PL6-2 13:50-14:15 PL6-3 14:15-14:40 PL6-4 Camille Sureau (Paris)/ Jaw-Ching Wu () HDV Virology and The Novel Therapy for Chronic Hepatitis D Mechanisms of Large Hepatitis Eelta Antigen Induced Epithelial-mesenchymal Transition: Implications of Novel therapy Taiwan-Mongolian Collaboration to Control HDV Infection in a Hyperendemic Area Natural History of Chronic Hepatitis D Virus Infection Camille Sureau Jaw-Ching Wu Davaadorj Duger Chien-Wei Su Paris Ulaanbaatar State-of-art Lecture 15:30-16:00 Ding-Shinn Chen () 15:30-16:00 Global Elimination of Hepatitis B: Taiwan Experiences and International Collaborations Chien-Jen Chen Chairman Lecture 16:00-16:30 Yun-Fan Liaw () 16:00-16:30 (To be advised) Rong-Nan Chien Linkou Keynote Lecture (I) 16:30-17:00 Masao Omata (Kofu) 16:30-17:00 HBeAg-negative Chronic HBV Infection: Natural Course and Management in the Light of HBsAg Quantification Yun-Fan Liaw

6 June 24 (Sun) Keynote Lecture (II) 09:00-09:30 Mei-Hwei Chang () 09:00-09:30 Toward Global Elimination of Hepatitis B Anna Suk-Fong Lok Ann Arbor Keynote Lecture (III) 09:30-10:00 Pei-Jer Chen () 09:30-10:00 Research on HBV life Cycle and Drug Discovery Takaji Wakita Tokyo Plenary Session (VII): HBV Challenges and Opportunities in the Treatment of CHB 10:20-12:00 Lik Yuen Henry Chan (Hong Kong)/ Chun-Jen Liu () 10:20-10:45 PL7-1 Unmet Needs of CHB after NUC Treatment Lik Yuen Henry Chan Hong Kong 10:45-11:10 PL7-2 11:10-11:35 PL7-3 11:35-12:00 PL7-4 Management of CHB Sub-populations with Grey Zone Treatment Indications NUC for CHB: Discontinued Versus Continuous Strategy Reactivation of HBV in Special Clinical Settings: Risk and Management Tai-Chung Tseng Yi-Cheng Chen Chun-Jen Liu

7 Plenary Session (VIII): HCC Recent Advance in the Treatment of Hepatocellular Carcinoma Room 201DEF 10:20-12:00 10:20-10:45 PL8-1 10:45-11:10 PL8-2 Ryosuke Tateishi (Tokyo)/ Yi-Hsiang Huang () Advance in radiofrequency ablation therapy for HCC Advance in Drug-elution Bead TACE and SIRT for HCC Ryosuke Tateishi Yoon-Jun Kim Tokyo Seoul 11:10-11:35 PL8-3 Proton Beam Therapy for HCC Ji-Hong Hong Taoyuan 11:35-12:00 PL8-4 Advance in Immune Checkpoint Inhibitors for HCC Ann-Lii Cheng Special Lecture 13:20-13:40 Jia-Horng Kao () 13:20-13:40 Human Genomics AND Hepatitis B Masashi Mizokami Tokyo Plenary Session (IX): HBV Vaccination The Success and Challenge of HBV Vaccination 13:40-15:20 Yong Poovorawan (Bangkok)/ Yen-Hsuan Ni () 13:40-14:05 PL9-1 Global Strategies of Hepatitis B Vaccination: The Past, Present and Future Mei-Hwei Chang 14:05-14:30 PL9-2 The Implementation of HBV Vaccination in SouthEast Asia Yong Poovorawan Bangkok 14:30-14:55 PL9-3 How to Convince people to Implement Universal Vaccination in a Low-endemic Area? Ayano Inui Yokohama 14:55-15:20 PL9-4 Elimination of Mother-to-child Transmission of HBV Huey-Ling Chen

8 Individual Guidelines and Reimbursement Policy on HBV Workshop 13:40-15:20 Yun-Fan Liaw ()/ Anna Suk-Fong Lok (Ann Arbor)/ Masao Omata (kofu) 13:40-13:49 IG-1 (To be advised) Jacob George (TBC) Australia 13:49-13:58 IG-2 The Hong Kong Situation Vincent Wai-sun Wong Hong Kong 13:58-14:07 IG-3 The JSH Guideline for the Antiviral Treatment of Hepatitis B Virus Infection and Current Issues in Japan Tetsuya Hosaka Tokyo 14:07-14:16 IG-4 Korean Guideline and Reimbursement Policy on HBV Young-Suk Lim Seoul 14:16-14:25 IG-5 (To be advised) Oidov Baatarkhuu (TBC) 14:25-14:34 IG-6 Current State of Hepatitis B in the Philippines Stephen N. Wong Manila 14:34-14:43 IG-7 14:43-14:52 IG-8 14:52-15:01 IG-9 15:01-15:10 IG-10 15:10-15:19 IG-11 Update Reimbursement Guidelines of HBV Therapy in Taiwan and the Long-term Outcomes Management of Hepatitis B in India: Current Guidelines A Community Based Hepatitis B Programme in New Zealand to Eliminate Hepatitis B Challenges towards Elimination of Hepatitis B in Malaysia Jia-Horng Kao Anil Arora Susan Hay The Evolving HBV Guidelines and Ji-Dong Jia Reimbursement Policies in Mainland China (TBC) New Delhi Whakatane Rosmawati Mohamed Kuala Lumpur

2011 International Conference of Inflammation, Cancer and Metabolic Disorders Program

2011 International Conference of Inflammation, Cancer and Metabolic Disorders Program Friday, November 4 th, 2011 09:00-09:30 Registration 09:30-09:40 Welcome & Opening Remarks Kenneth K. Wu, M.D., Ph.D. Fu-Tong Liu, M.D., Ph.D. Plenary Lecture I Chair: Kenneth K. Wu, M.D., Ph.D. 09:40-10:40

More information

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

Journal of Chinese Medicine. Vol.20, No.1, Vol.20, No.3,

Journal of Chinese Medicine. Vol.20, No.1, Vol.20, No.3, 163 Journal of Chinese Medicine Vol.20, No.1,2 1-96 Vol.20, No.3,4 97-162 ~ - 145 45-135 21 117 79-19 137-135 ~ - 137 65 87-65 - 145-65 - 153-79 - 153-87 47-137 - 65-87 - 47-145 - 145-47 - 19 164 153 HT7

More information

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and

More information

2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities ( 2017:27: (07)

2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities ( 2017:27: (07) 116 2013 1 2 2 1 3 4 5 6 7 8 9 2 10 11 2 12 13 14 15 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 2025 2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities

More information

Hepatitis B virus (HBV) infection is an important. Brief Communication

Hepatitis B virus (HBV) infection is an important. Brief Communication Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,

More information

Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J

Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J 97 Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J Chun-Jen Liu, MD, PhD 1,2,3 Jia-Horng Kao, MD, PhD 1,2,3,4 1 Graduate Institute of Clinical

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

Hepatitis B virus (HBV) infection is a global

Hepatitis B virus (HBV) infection is a global VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung

More information

Index : Bridging Asia to the World- A New Era for Psychiatric Treatment

Index : Bridging Asia to the World- A New Era for Psychiatric Treatment 1 Index : 2 3 Mood disorders President Tung-Ping Su Honorary president Shigeto Yamawaki Division of Psychiatry, Faculty of Medicine, National Yang-Ming University Department of Psychiatry and Neurosciences,

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

CURRICULUM VITAE. Name: PoTsung Chen, Ph.D.

CURRICULUM VITAE. Name: PoTsung Chen, Ph.D. CURRICULUM VITAE Name: PoTsung Chen, Ph.D. #1 University Rd, Dept. of Architecture, NCKU Tainan, Taiwan, 701 Tel:886-6-252-1019 Fax:886-6-281-0380 Email:potsung@mail.ncku.edu.tw (1)Personal Information:

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

Chronic Hepatitis. Basic Science to Clinical Applications. and. Chronic Hepatitis B and C Downloaded from

Chronic Hepatitis. Basic Science to Clinical Applications. and. Chronic Hepatitis B and C Downloaded from Chronic Hepatitis B C and Basic Science to Clinical Applications This page intentionally left blank Chronic Hepatitis B and C Basic Science to Clinical Applications Editor Chiaho Shih Academia Sinica,

More information

HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN

HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN UNIVERSAL HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN MEI-HWEI CHANG, M.D., CHIEN-JEN CHEN, SC.D., MEI-SHU LAI, M.D., HSU-MEI HSU, M.P.H., TZEE-CHUNG WU,

More information

The 12th Japan-Taiwan Symposium on. Emerging and re-emerging infectious diseases, Vaccine Preventable Diseases and Collaborative Project Reports

The 12th Japan-Taiwan Symposium on. Emerging and re-emerging infectious diseases, Vaccine Preventable Diseases and Collaborative Project Reports The 12th Japan-Taiwan Symposium on Emerging and re-emerging infectious diseases, Vaccine Preventable Diseases and Collaborative Project Reports September 10-11, 2015 National Institute of Infectious Diseases,

More information

Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study

Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study ARTICLE Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study Mei-Hwei Chang, San-Lin You, Chien-Jen Chen, Chun-Jen Liu, Chuan-Mo Lee, Shi-Ming Lin, Heng-Cheng

More information

Appendix 5 Members of the Chinese Medicine Council of Hong. Kong, Chinese Medicine Practitioners Board, Chinese

Appendix 5 Members of the Chinese Medicine Council of Hong. Kong, Chinese Medicine Practitioners Board, Chinese Appendix 5 Members of the Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees and of the Chinese Medicine Council of Hong Kong a chairman;

More information

VOICES OF THE HIDDEN

VOICES OF THE HIDDEN VOICES OF THE HIDDEN I M P L E M E N TAT I O N O F T H E P E O P L E L I V I N G W I T H H I V S T I G M A I N D E X I N TA I WA N Yi-Chi Chiu 1, 2, Ting-Shu Wu 1, Yuan-Ti Lee 3, 4, Ning-Chi Wang 5, Wing-Wai

More information

Curriculum Vitae. B. S. Department of Nutrition and Food Sciences

Curriculum Vitae. B. S. Department of Nutrition and Food Sciences Name: Young, Guang-Huar Curriculum Vitae Address: 2F.-1, No.6, Ln. 144, Anle Rd., Yonghe Dist., New Taipei City 23455, Taiwan (R.O.C.) Tel: 886-2-29491565 E-mail: r6623612@ms24.hinet.net; youngguanghuar@gmail.com

More information

Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants

Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1

More information

Treatment of Non-cirrhotic Incarcerated Genotype 6 Chronic Hepatitis C Injection Drug Users, Compared with Genotype 1

Treatment of Non-cirrhotic Incarcerated Genotype 6 Chronic Hepatitis C Injection Drug Users, Compared with Genotype 1 DOI 10.6314/JIMT.201812_29(6).06 2018 29 393-400 Treatment of Non-cirrhotic Incarcerated Genotype 6 Chronic Hepatitis C Injection Drug Users, Compared with Genotype 1 Lian-Feng Lin 1,3, Yi-Chun Chan 1,

More information

Update on Biology and Clinical Impact of Occult Hepatitis B Virus Infection

Update on Biology and Clinical Impact of Occult Hepatitis B Virus Infection Update on Biology and Clinical Impact of Occult Hepatitis B Virus Infection Taormina-MeSSINA-Italy October 1 st 2 nd 2018 1 Update on Biology and Clinical Impact of Occult Hepatitis B Virus Infection Taormina-MeSSINA-Italy

More information

Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance

Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance /, 2017, Vol. 8, (No. 27), pp: 43925-43933 Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance Chung-Feng Huang 1,2, Ming-Lun

More information

During the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B

During the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Yao-Shih Hsu, 1 Rong-Nan Chien, 1 Chau-Ting Yeh, 1 I-Shyan Sheen, 1 Hung-Yi Chiou, 2 Chia-Ming Chu, 1 and Yun-Fan

More information

Members of The Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees

Members of The Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees Members of The Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees and of the Chinese Medicine Council of Hong Kong (e) (f) (g) a chairman;

More information

Chronic infection with hepatitis B virus (HBV) is still a

Chronic infection with hepatitis B virus (HBV) is still a CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:527 534 Incidence and Determinants of Spontaneous Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B HWAI I YANG,*,, HSIU LIAN HUNG, MEI

More information

Received 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004

Received 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004 JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2004, p. 5036 5040 Vol. 42, No. 11 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.11.5036 5040.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.

More information

Hepatitis C Virus Disease

Hepatitis C Virus Disease Hepatitis C Virus Disease Emilio Jirillo Editor Hepatitis C Virus Disease Immunobiology and Clinical Applications Editor Emilio Jirillo University of Bari and National Institute for Digestive Disease Castellana

More information

Symposia October 20 th (Fri.) 17:00-18:15

Symposia October 20 th (Fri.) 17:00-18:15 Symposia October 20 th (Fri.) 17:00-18:15 Session A: Global Perspectives in Professional Practice A-1 The Objective Structured Clinical Examination in Pediatric Occupational Therapy Room: 2F-C202 Chung

More information

Disclosures. Grant: Arrowhead Pharmaceuticals

Disclosures. Grant: Arrowhead Pharmaceuticals Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen Man-Fung Yuen * 1, Kevin

More information

Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54

Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54 CORRECTION NOTICE Nat. Genet. 42, 759 763 (2010); published online 22 August 2010; corrected online 27 August 2014 Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects

More information

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the

More information

Name List of Scout of the Year

Name List of Scout of the Year Name List of Scout of the Year Name Sex Section Group Year of Award 1. Jimmy TONG Chun-kuen M Cub Scout 14 th Hong Kong Group 1987 2. YIP Chi-kwong M Scout 98 th Kowloon Group 1987 3. Wilfred MAK Wai-fung

More information

Treatment of HCC in real life-chinese perspective

Treatment of HCC in real life-chinese perspective Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

NATURAL HISTORY OF HEPATITIS B

NATURAL HISTORY OF HEPATITIS B NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

REGIONAL OFFICE FOR THE WESTERN PACIFIC BUREAU REGIONAL DU PACIFIQUE OCCIDENTAL

REGIONAL OFFICE FOR THE WESTERN PACIFIC BUREAU REGIONAL DU PACIFIQUE OCCIDENTAL W O R L D H E A L T H ORGANIZATION ORGANISATIONS MONDIALE DE LA SANTE REGIONAL OFFICE FOR THE WESTERN PACIFIC BUREAU REGIONAL DU PACIFIQUE OCCIDENTAL EXPERTS' CONSULTATION MEETING WPR/DHS/EMT(2)/2010/IB/2

More information

Title: Off therapy durability of response to Entecavir therapy in hepatitis B e

Title: Off therapy durability of response to Entecavir therapy in hepatitis B e Title: Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients Wen-Juei Jeng, MD 1,3, I-Shyan Sheen, MD 1-3, Yi-Cheng Chen, MD 1,3, Chao-Wei

More information

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer

More information

Does Viral Cure Prevent HCC Development

Does Viral Cure Prevent HCC Development Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,

More information

HBV in New Zealand Community HBV screening to long-term follow-up

HBV in New Zealand Community HBV screening to long-term follow-up HBsAg+ icteric hepatitis (n) % anti-hbcore+ 26/9/214 HBV in New Zealand Community HBV screening to long-term follow-up John Hornell, CEO, A registered charitable trust whose mission is: To improve health

More information

Hepatocellular carcinoma (HCC) is still one of the. Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan

Hepatocellular carcinoma (HCC) is still one of the. Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan HEPATOBILIARY MALIGNANCIES Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan Yen-Po Yeh, 1 Tsung-Hui Hu, 2 Po-Yuan Cho, 3 Hsiu-Hsi Chen, 4 Amy Ming-Fang Yen,

More information

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011 HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary

More information

Asian-Oceanian Journal of Pediatrics and Child Health JAPANESE PEDIATRIC BOARD CERTIFICATION: HISTORY AND FUTURE PERSPECTIVES

Asian-Oceanian Journal of Pediatrics and Child Health JAPANESE PEDIATRIC BOARD CERTIFICATION: HISTORY AND FUTURE PERSPECTIVES Asian-Oceanian Journal of Pediatrics and Child Health Volume One December 2002 Number Two JAPANESE PEDIATRIC BOARD CERTIFICATION: HISTORY AND FUTURE PERSPECTIVES Nobutake Matsuo, M.D. (1), John Ichiro

More information

Chronic hepatitis B (CHB) infection is a large

Chronic hepatitis B (CHB) infection is a large AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

More information

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection Tung-Hung Su 1,2,3, Chun-Jen Liu 1,2,3, Tai-Chung Tseng 2,4, Chen-Hua Liu 1,2,3, Hung-Chih Yang 1,5, Chi- Ling Chen

More information

New Treatments for HCV: Perspective From Asia

New Treatments for HCV: Perspective From Asia REVIEW New Treatments for HCV: Perspective From Asia Ming-Lung Yu, M.D., Ph.D.,*, Wan-Long Chuang, M.D., Ph.D.*, Introduction The prevalence and number of people with antibodies to hepatitis C virus (anti-hcv)

More information

Name: Shun-Te Huang. Tel: ext.2272

Name: Shun-Te Huang.   Tel: ext.2272 Name: Shun-Te Huang Email: shuntehuang@gmail.com Tel: 886-7-3121101 ext.2272 EDUCATION: Ph. D. 1979-1983 Department of Pediatric Dentistry, Graduate School of Dentistry, Osaka dental University. Japan

More information

Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients

Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients VIRAL HEPATITIS Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Wen-Juei Jeng, 1,2 I-Shyan Sheen, 1,2 Yi-Cheng Chen, 1,2 Chao-Wei

More information

Chang Gung Medical Journal

Chang Gung Medical Journal Vol. 33 No. 2 March-April 2010 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 115 The Role of Insulin Receptor Signaling in Synaptic Plasticity and Cognitive Function Chiung-Chun Huang, PhD;

More information

RONG-NAN CHIEN, 1 YUN-FAN LIAW, 1 AND MARK ATKINS 2 FOR THE ASIAN HEPATITIS LAMIVUDINE TRIAL GROUP

RONG-NAN CHIEN, 1 YUN-FAN LIAW, 1 AND MARK ATKINS 2 FOR THE ASIAN HEPATITIS LAMIVUDINE TRIAL GROUP Pretherapy Alanine Transaminase Level as a Determinant for Hepatitis B e Antigen Seroconversion During Lamivudine Therapy in Patients With Chronic Hepatitis B RONG-NAN CHIEN, 1 YUN-FAN LIAW, 1 AND MARK

More information

CMU Faculty Profile Yu-Chen Lee

CMU Faculty Profile Yu-Chen Lee Yu-Chen Lee Dean, Acupuncture department of China Medicine University Hospital Assistant Professor, Graduate Institution of Acupuncture Sciences, China Medicine University Ph.D., China Medicine University

More information

White Nights of Hepatology 2016

White Nights of Hepatology 2016 White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow

More information

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD CLINICAL OFFICES Digestive Health Liver Clinic 900 Blake Wilbur Dr MC 5355 Palo Alto, CA 94304 Tel (650) 498-7999 Fax (650) 724-9454 Liver Transplant Clinic 300 Pasteur Dr A160 Bio MC 5309 Stanford, CA

More information

Asia Pacific Heart Rhythm Society PHYSICIAN EDUCATION PROGRAM: CARDIAC RHYTHM DEVICE THERAPY

Asia Pacific Heart Rhythm Society PHYSICIAN EDUCATION PROGRAM: CARDIAC RHYTHM DEVICE THERAPY Asia Pacific Heart Rhythm Society PHYSICIAN EDUCATION PROGRAM: CARDIAC RHYTHM DEVICE THERAPY Organized by APHRS VIRTUAL REALITY PROGRAMMING WORKSHOPS Sponsored by educational grant from St. Jude Medical

More information

Agenda of the 5 th Hong Kong International Oncology Symposium

Agenda of the 5 th Hong Kong International Oncology Symposium Day 1 Program of the 5 th HKIOS (10 th November 2018) Venue: The Hong Kong Science Park Time Name of Speaker Name of Presentation Topic Affiliations of the Speaker 08:40 08:50 Joseph Siu Kie AU Welcome

More information

Chang Gung Medical Journal

Chang Gung Medical Journal Vol. 34 No. 1 January-February 2011 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 1 Surface Anthropometric Indices in Obesity-related Metabolic Diseases and Cancers Chao-Yang Yang, PhD;

More information

Name List of Scout of the Year

Name List of Scout of the Year Name List of Scout of the Year Name Sex Section Group Year of Award 1. Jimmy TONG Chun-kuen M Cub Scout 14 th Hong Kong Group 1987 2. YIP Chi-kwong M Scout 98 th Kowloon Group 1987 3. Wilfred MAK Wai-fung

More information

Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection

Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection PO Box 2345, Beijing 123, China World J Gastroenterol 25;11(43):6848-6852 www.wjgnet.com World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com E L S E V I E R 25 The WJG Press and Elsevier Inc.

More information

What have we learned from HBV clinical cohorts?

What have we learned from HBV clinical cohorts? PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National

More information

Hepatitis B and D Update on clinical aspects

Hepatitis B and D Update on clinical aspects Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy

More information

News Letter. Thanks letter AOCC2014. Asian Organization for Crohn s and Colitis. Vol.1 - Issue 1. Dear Colleagues, Dear Participants,

News Letter. Thanks letter AOCC2014. Asian Organization for Crohn s and Colitis. Vol.1 - Issue 1. Dear Colleagues, Dear Participants, Vol. - Issue Thanks letter AOCC04 Dear Colleagues, Dear Participants, On behalf of the Governing Board, I would like to express my appreciation for your dedicated participation on The Second Annual Meeting

More information

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections

More information

Chang Gung Medical Journal

Chang Gung Medical Journal Vol. 32 No. 5 September-October 2009 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 471 C-reactive Protein and Malignancy: Clinico-pathological Association and Therapeutic Implication Chia-Siu

More information

Hepatitis B virus (HBV) is a significant cause of

Hepatitis B virus (HBV) is a significant cause of Secular Trend of the Viral Genotype Distribution in Children With Chronic Hepatitis B Virus Infection After Universal Infant Immunization Wan-Hsin Wen, 1,6,7 Huey-Ling Chen, 1,2 Yen-Hsuan Ni, 1 Hong-Yuan

More information

TOP PAPERS FOR TAIWAN IN SOCIAL SCIENCES, GENERAL

TOP PAPERS FOR TAIWAN IN SOCIAL SCIENCES, GENERAL 頁 1 / 8 TOP PAPERS FOR TAIWAN IN Sorted by: Citations 1-20 (of 27) [ 1 2 ] Page 1 of 2 1 Citations: 406 THREE APPROACHES TO QUALITATIVE CONTENT ANALYSIS HSIEH HF; SHANNON SE QUAL HEALTH RES 15 (9): 1277-1288

More information

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse. Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,

More information

Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients

Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients Original Article 250 Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients Chen Chih Liao 1, Chao Wei Hsu 1,

More information

Inarigivir: A novel RIG-I agonist for chronic hepatitis B

Inarigivir: A novel RIG-I agonist for chronic hepatitis B : A novel RIG-I agonist for chronic hepatitis B Stephen Locarnini, Danny Wong, Kathy Jackson, Renae Walsh, Ros Edwards, Rachel Hammond, Carla S. Coffin, Magdy Elkhashab, Susan Greenbloom, Alnoor Ramji,

More information

Management of Chronic Hepatitis B in Asian Americans

Management of Chronic Hepatitis B in Asian Americans Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,

More information

Min Weng, Wei-Zheng Zeng *, Xiao-Ling Wu, Yong Zhang, Ming-De Jiang, Zhao Wang, De-Jiang Zhou and Xuan He

Min Weng, Wei-Zheng Zeng *, Xiao-Ling Wu, Yong Zhang, Ming-De Jiang, Zhao Wang, De-Jiang Zhou and Xuan He Weng et al. Virology Journal 2013, 10:277 RESEARCH Open Access Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis

More information

Response-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon

Response-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis

More information

Antiviral Therapy 14:

Antiviral Therapy 14: Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,

More information

Mechanis%c comparison of RNAi therapeu%cs vs. reverse transcriptase inhibitors (NUCs)

Mechanis%c comparison of RNAi therapeu%cs vs. reverse transcriptase inhibitors (NUCs) Effec%ve Inhibi%on of cccdna derived mrna/viral An%gens and Tolerability with ARC-520 25 th APASL Conference, 2016 Man-Fung Yuen, MD, PhD The University of Hong Kong On behalf of the Heparc-1001 and Heparc-2001

More information

Y. Xiang*, P. Chen*, J.R Xia and L.P. Zhang

Y. Xiang*, P. Chen*, J.R Xia and L.P. Zhang A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies Y. Xiang*, P. Chen*,

More information

Lunch time (TICC, 4F VIP dining hall) IADR-SEA pre-conference workshops I. SEAADE Oral Presentation. SEAADE Oral Presentation

Lunch time (TICC, 4F VIP dining hall) IADR-SEA pre-conference workshops I. SEAADE Oral Presentation. SEAADE Oral Presentation Date Thursday, August 10 th 2017 Taipei International Convention Center, Taipei, Taiwan # South 09:00~17:00 P-001-023 Poster Viewing 9:00 EK-01 Corrado Paganelli European dental education: Geriatric dentistry

More information

Chang Gung Medical Journal

Chang Gung Medical Journal Vol. 34 No. 3 May-June 2011 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 229 Direct Activation of Bmi1 by Twist1: Implications in Cancer Stemness, Epithelial- Mesenchymal Transition, and

More information

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute

More information

High Hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study

High Hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study High Hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study ArticleCategory ArticleHistory : Research : Received:

More information

The 1 st Congress of Asian Society of Cardiovascular Imaging

The 1 st Congress of Asian Society of Cardiovascular Imaging The 1 st Congress of Asian Society of Cardiovascular Imaging April 27 (Friday) ~ April 28 (Saturday), 2007 Asan Medical Center, Seoul, Korea Number of Participants : 545 Participants from 26 Countries

More information

Chronic hepatitis B virus (HBV) infection remains a major

Chronic hepatitis B virus (HBV) infection remains a major CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,

More information

Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis

Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Author's response to reviews Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Authors: Mei-Yin Zhang (zhangmy@sysucc.org.cn) Shu-Hong

More information

Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis

Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic

More information

An Update HBV Treatment

An Update HBV Treatment An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard

More information

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay

More information

Checkpoint inhibitors for HBV cure

Checkpoint inhibitors for HBV cure Checkpoint inhibitors for HBV cure Mala Maini Division of Infection and Immunity UCL, London Toronto HBV Cure 2016 Reversal of T cell exhaustion: the goal of checkpoint inhibitors CD8 T cells Granzyme

More information

EDUCATION/TRAINING INSTITUTION AND LOCATION

EDUCATION/TRAINING INSTITUTION AND LOCATION NAME 包大靝 Bau, Da-Tian POSITION TITLE Professor EDUCATION/TRAINING INSTITUTION AND LOCATION National Taiwan University, Taiwan National Defense Medical Center, Taiwan National Defense Medical Center, Taiwan

More information

HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium

HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Anchorage, Alaska USA Goals of My Lecture Highlight the

More information

TABLE OF CONTENTS. Title page 1. Chinese abstract 2. English abstract 3. Introduction 4. Result 8. Discussion 11. Acknowledgement 12.

TABLE OF CONTENTS. Title page 1. Chinese abstract 2. English abstract 3. Introduction 4. Result 8. Discussion 11. Acknowledgement 12. 行 度 理 療 異 度 類 行 年 年 行 立 理 年 TABLE OF CONTENTS Title page 1 Chinese abstract 2 English abstract 3 Introduction 4 Result 8 Discussion 11 Acknowledgement 12 Reference 13 Evaluation 16 Analysis of HBV-specific

More information

Hepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan

Hepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan Original Article 137 Hepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan Chang-Jung Chang 1, MD; Jui-Chin Chiang 1,2,6, MD; Sheng-Nan

More information

Hepatitis B (and D) Cure Strategies: How far are we?

Hepatitis B (and D) Cure Strategies: How far are we? Hepatitis B (and D) Cure Strategies: How far are we? Heiner Wedemeyer Dept. of Gastroenterology and Hepatology Essen University Hospital International Hepatitis E Symposium February 14-16, 2019 H. Wedemeyer

More information

Journal of Antimicrobial Chemotherapy Advance Access published April 25, 2013

Journal of Antimicrobial Chemotherapy Advance Access published April 25, 2013 Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression

More information

EMPEROR'S COLLEGE MTOM COURSE SYLLABUS MEDICAL QI GONG I

EMPEROR'S COLLEGE MTOM COURSE SYLLABUS MEDICAL QI GONG I COURSE DESCRIPTION Qi Gong is a form of art that utilizes one s intentions, breathing techniques, and subtle body movements to control the flow of qi in one s body, or that of a surrounding object. This

More information

ART ICLEHepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men

ART ICLEHepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men ART ICLEHepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men Ming-Whei Yu, Shiou-Hwei Yeh, Pei-Jer Chen, Yun-Fan Liaw, Chih-Lin Lin, Chun-Jen Liu, Wei-Liang

More information

Liu Jing and Liu Jing Diagnosis System in Classical TCM Discussions of Six Divisions or Six Confirmations Diagnosis System in Classical TCM Texts

Liu Jing and Liu Jing Diagnosis System in Classical TCM Discussions of Six Divisions or Six Confirmations Diagnosis System in Classical TCM Texts Liu Jing and Liu Jing Diagnosis System in Classical TCM Discussions of Six Divisions or Six Confirmations Diagnosis System in Classical TCM Texts Liu Jing Bian Zheng system had developed about 1800 years

More information